All Insights

The obesity drug race is moving beyond headline weight-loss numbers. This article compares leading and emerging therapies across efficacy, safety, health benefits, treatment durability, and convenience—and examines what those differences could mean for patients and investors.

Leqembi and Kisunla established anti-amyloid therapy as a disease-modifying strategy in early Alzheimer’s disease, but their success also exposed important limitations. This article examines ARIA, diagnosis, drug delivery, and emerging technologies that could shape the next generation of Alzheimer’s treatment.

CGRP therapies transformed migraine treatment, but the next generation of drugs faces a higher bar. This article examines PACAP as an emerging pathway, the clinical evidence behind bocunebart, and what Phase 3 must prove for a new mechanism to achieve meaningful clinical and commercial differentiation.

The 340B program can materially shape healthcare deal economics, but its impact is often hidden within reported earnings. This article examines how investors can separate durable operating performance from 340B-dependent profits, quantify regulatory downside through EBITDA sensitivity analysis, and incorporate that exposure into valuation, leverage, and investment decisions.

AbbVie paid $2.1 billion for a biotech with no published human data. Here's what the science actually shows — and doesn't show — about whether the bet holds up.

Sam Altman says AI will transform education. The venture funding data tells a different story — the money goes to habit-forming practice apps, not tools that verify real learning. Meanwhile the US, EU, and China are running three genuinely different bets on how AI belongs in the classroom, and none of them are finished. This is a status check on where things actually stand, not another prediction piece.

Building AI sounds like something only a handful of billion-dollar labs can do. It isn't — using AI, building with it, fine-tuning it, and even training a narrow model from scratch are all realistic for one motivated person. This piece breaks down the five real levels of "building AI," with real companies (Cursor, Harvey, Sanofi, Microsoft) at each one, plus a step-by-step guide to building your own AI-powered tool this week.

While Mars gets the headlines, four governments are quietly racing to claim and defend a layer of infrastructure a few hundred kilometers overhead — and none of them are doing it entirely alone.

Americans favor real estate over stocks nearly two to one, even though stocks have the better long-run average return. This piece breaks down why leverage — not raw returns — explains the gap, then shows two realistic scenarios where the same framework produces opposite winners, and a third where the winner flips again depending on how long you hold. Includes what the model deliberately leaves out: taxes, liquidity, and active management effort.

U.S. health care spending hit $5.3 trillion in 2024 — more than any other country, despite the U.S. not even being the world's richest per capita. This piece breaks down the real reasons why (paperwork, physician pay, undernegotiated drug prices), how Germany, Japan, and Singapore keep costs down instead, which U.S. fixes are already underway, and where each of those dynamics creates a distinct opportunity for different types of investors.